Interleukin 6 inhibitors in the treatment of rheumatoid arthritis Interleukin 6 inhibitors in the treatment of rheumatoid arthritis Interleukin 6 inhibitors in the treatment of rheumatoid arthritis Interleukin 6 onhibitors in the treatment of rheumatoid arthritis
2018
Abstract
Interleukin 6 (IL-6) plays an important role in the pathogenesis of rheumatoid arthritis. Currently, two different monoclonal antibodies to IL-6 receptors: tocilizumab and sarilumab are registered for the treatment of rheumatoid arthritis.
Sirukumab, a monoclonal antibody against the IL-6 molecule, is currently in Phase III clinical testing. The text provides an overview of basic clinical trials focused on the efficacy of IL-6 blockers in the treatment of rheumatoid arthritis